Fundacion GECP — Sponsor Intelligence | 14 EU Trials

Filter these 14 trials by condition, phase, country and more.

Open in Search →

14 Registered trials

5 Recruiting

9 Completed trials

8 Countries active

16 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 3 Phase II: 11

100%

9 of 9 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 6 Small cell lung cancer limited stage 1 Small cell lung cancer extensive stage 1 Pancoast's tumour 1 Non-small cell lung cancer stage III 1

Top IMPs

NIVOLUMAB 4 CARBOPLATIN 3 PACLITAXEL 3 ATEZOLIZUMAB 2 BRIGATINIB 1 CEMIPLIMAB 1 DURVALUMAB 1 IPILIMUMAB 1 LENVATINIB 1 PEMBROLIZUMAB 1 PEMETREXED 1 RIFAXIMIN 1

All trials

14 total

Phase II study on the safety and feasibility of stool transplants in limited non-small cell lung cancer patients, using donors who responded… Recruiting

2025-521251-24-00 Phase II 1 country CARBOPLATIN; DURVALUMAB; PACLITAXEL; RIFAXIMIN
Phase II study of tarlatamab as a follow-up treatment after chemo and radiation in patients with small cell lung cancer (SCLC) who cannot re… Recruiting

2024-515201-26-00 Phase II 1 country TARLATAMAB
Study of the treatment of patients with non-small cell lung cancer with metastasis with Cemiplimab and subsequent treatment with Cemiplimab … Recruiting

2024-518812-38-00 Phase II 1 country CARBOPLATIN; CEMIPLIMAB; PACLITAXEL; PEMETREXED
Phase II clinical trial of chemotherapy + atezolizumab for stage IIIa and IIIb non-small cell lung cancer followed by atezolizumab as adjuva… Recruiting

2024-515984-68-00 Phase II 1 country ATEZOLIZUMAB; CARBOPLATIN; PACLITAXEL
Study of treatment with sacituzumab and zimkberelimab for patients with lung cancer confined to the chest and previously operated on who wer… Recruiting

2024-512960-75-00 Phase III 1 country SACITUZUMAB GOVITECAN; ZIMBERELIMAB
Study of chemotherapy and immunotherapy before and after surgery in patients with non-small cell lung cancer whose tumor is located in the u… Ended

2024-512359-19-00 Phase II 1 country NIVOLUMAB
Study of pembrolizumab, lenvatinib and chemotherapy combination in first line lung cancer Ended

2024-511412-25-00 Phase II 1 country LENVATINIB; PEMBROLIZUMAB
A research study to evaluate the activity of Sotorasib for the treatment of patients with non-operable non-small cell lung cancer with a KRA… Ended

2024-511268-10-00 Phase II 1 country SOTORASIB
Study of Nivolumab and Ipilimumab plus chemotherapy as a treatment for patients with stage IV lung cancer with brain metastases. Ended

2024-513866-20-00 Phase II 1 country IPILIMUMAB; NIVOLUMAB
"Study of chemotherapy vs immunotherapy for patients with lung cancer bounded in the thorax and completely resected" Ended

2024-513730-38-00 Phase III 1 country NIVOLUMAB
Utility of analysis in blood of the evolution of the drug brigatinib for patients with lung cancer with ALK mutations Ended

2024-511317-38-00 Phase II 1 country BRIGATINIB
Study of Atezolizumab plus chemotherapy plus chemo-radiotherapy and Atezolizumab maintenance therapy in non-resectable non-small cell lung c… Ended

2024-514803-33-00 Phase II 1 country ATEZOLIZUMAB
Study of chemotherapy and immunotherapy for patients with lung cancer bounded in the thorax and potentially resectable Ended

2024-513731-24-00 Phase II 1 country NIVOLUMAB
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Can… Ended

2024-517856-36-00 Phase III 8 countries

Showing 1–14 of 14 trials

← All sponsors A–Z